CD8A and melanoma: In two advanced melanoma patients, in silico prediction of HLA binding affinity exhibited only 0.4% (2 of 501) and 1.3% (3 of 226) of neoantigens could trigger the neoantigen-specific CD8+ T cells responses [30].